Patent · US Active

Chimpanzee adenoviral vector-based filovirus vaccines

US10584355B2 · kind B2 · utility

0Cited by

3References

16Claims

0Family size

Assignees

The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services · US
GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Nancy Sullivan · Kensington, US
Gary J. Nabel · Cambridge, US
Clement Asiedu · Olney, US
Cheng Cheng · Bethesda, US
Alfredo Nicosia · Siena, IT
Riccardo Cortese · Roma, IT
Virginia Ammendola · Napoli, IT
Stefano Colloca · Roma, IT

Key dates

Filing date	Oct 31, 2016
Grant date	Mar 10, 2020
Priority date	—
Expiry date	Oct 31, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/14134
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.